Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Nicholas G. Davies, Christopher I Jarvis, W. John Edmunds, Nicholas P. Jewell, Karla Díaz-Ordaz, Ruth H. Keogh

Abstract

SARS-CoV-2 lineage B.1.1.7, first detected in the United Kingdom in September 2020, has spread globally. While several studies established that B.1.1.7 is more transmissible than preexisting variants, its impact on disease severity remained unclear. We analyzed a dataset linking 2,245,263 positive community tests and 17,452 COVID-19 deaths in England from 1 September 2020 to 14 February 2021. Based on 4,945 deaths with known S-gene target failure (SGTF) status, we estimate that the hazard of death associated with B.1.1.7 is 55% (95% CI 39-72%) higher after adjustment for age, sex, ethnicity, deprivation, and other factors. Correcting for misclassification and missingness, we estimate a 61% (42-82%) higher hazard of death. Our analysis suggests that B.1.1.7 is not only more transmissible but also causes more severe illness.

Introduction

By late 2020, the emergence of the B.1.1.7 variant (Alpha) fundamentally changed the trajectory of the pandemic. While its increased transmissibility was quickly recognized, determining whether it also caused more severe disease was critical for public health planning. Measuring severity during an active outbreak is challenging due to confounding factors like testing patterns and healthcare capacity. This study isolates the "variant effect" by linking individual-level community testing data with comprehensive death records in England, allowing for granular adjustment of confounding variables.

Methods and Data

The study utilized three primary datasets from Public Health England: Pillar 2 community testing records, cycle threshold (Ct) values from Lighthouse Labs, and a comprehensive COVID-19 death line list. To identify B.1.1.7 cases, researchers used S-gene target failure (SGTF) as a proxy. B.1.1.7 carries a specific deletion in the spike gene that prevents PCR amplification of the S-gene target in certain assays.

Figure 1: Data distribution and survival analysis. Panels (a) and (b) show the distribution of samples and deaths over time. Panel (c) illustrates the divergence in estimated survival between SGTF (B.1.1.7) and non-SGTF cases.

The analysis employed Cox proportional hazards models to estimate the relative risk of death over a 28-day period. To address potential biases, the team used Inverse Probability Weighting (IPW) to correct for missing SGTF status and logistic growth models to account for SGTF misclassification early in the study period.

Key Results: Increased Hazard of Death

The primary finding is a significant increase in mortality associated with the B.1.1.7 variant. The adjusted hazard of death for SGTF cases was 1.55 (95% CI 1.39–1.72). After correcting for misclassification and missing data, this estimate rose to 1.61 (95% CI 1.42–1.82).

Figure 2: Hazard ratio estimates for B.1.1.7 versus non-B.1.1.7 variants. Panels (a-d) show the hazard ratio over time, while (e) displays sensitivity analyses across various model specifications.

A notable insight is that the hazard of death for B.1.1.7 appears to increase relative to other variants over the course of the infection. The hazard ratio was estimated at 1.14 on day 1 post-test, climbing to 2.24 by day 28. This suggests a potentially different disease progression or a more sustained high viral load, which the authors noted is supported by lower Ct values (higher viral concentrations) in B.1.1.7 samples.

Absolute Risk and Public Health Impact

While the relative increase in hazard is substantial, the absolute risk remains heavily dependent on age and sex. For a male aged 55–69, the absolute risk of death within 28 days of a positive community test increased from 0.6% to 0.9%. In females aged 85 or older, the risk jumped from 13% to 19%; for males in the same age bracket, it rose from 17% to 25%. The increased risk was remarkably consistent across 94% of the 104 different subgroups analyzed, including various ethnicities, regions, and levels of deprivation.

Discussion and Limitations

This study provides strong evidence that B.1.1.7 is more lethal than previous variants. However, some limitations apply. The analysis focused on community-tested individuals, potentially excluding those who presented directly to hospitals without a prior community test. Additionally, the study occurred during the early stages of the UK's vaccination rollout and could not account for individual vaccination status. Despite these limitations, the findings underscore the importance of monitoring variant severity alongside transmissibility to inform public health responses.

Summary updated

Abstract

SARS-CoV-2 lineage B.1.1.7, a variant first detected in the United Kingdom in September 2020<sup>1</sup>, has spread to multiple countries worldwide. Several studies have established that B.1.1.7 is more transmissible than preexisting variants, but have not identified whether it leads to any change in disease severity<sup>2</sup>. We analyse a dataset linking 2,245,263 positive SARS-CoV-2 community tests and 17,452 COVID-19 deaths in England from 1 September 2020 to 14 February 2021. For 1,146,534 (51%) of these tests, the presence or absence of B.1.1.7 can be identified because of mutations in this lineage preventing PCR amplification of the spike gene target (S gene target failure, SGTF<sup>1</sup>). Based on 4,945 deaths with known SGTF status, we estimate that the hazard of death associated with SGTF is 55% (95% CI 39-72%) higher after adjustment for age, sex, ethnicity, deprivation, care home residence, local authority of residence and test date. This corresponds to the absolute risk of death for a 55-69-year-old male increasing from 0.6% to 0.9% (95% CI 0.8-1.0%) within 28 days after a positive test in the community. Correcting for misclassification of SGTF and missingness in SGTF status, we estimate a 61% (42-82%) higher hazard of death associated with B.1.1.7. Our analysis suggests that B.1.1.7 is not only more transmissible than preexisting SARS-CoV-2 variants, but may also cause more severe illness.
BibTeX
@inproceedings{davies2021increased,
  author = {Nicholas G. Davies and Christopher I Jarvis and W. John Edmunds and Nicholas P. Jewell and Karla Díaz-Ordaz and Ruth H. Keogh and Ruth H. Keogh},
  title = {{Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7}},
  booktitle = {Nature},
  year = {2021},
  doi = {10.1038/s41586-021-03426-1},
}
Figure